Epigenetic drug may re-sensitize liver tumors to immunotherapy
NCT ID NCT05873244
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial investigates whether adding an epigenetic drug (CXD101) to an immunotherapy (Geptanolimab) can help patients with advanced liver cancer whose disease has stopped responding to prior checkpoint inhibitors. The study enrolls about 26 adults with hepatocellular carcinoma who have previously received immunotherapy. Participants receive either the combination therapy or a standard targeted therapy (lenvatinib or sorafenib). The main goal is to see if the combination improves progression-free survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Zabadinostat (CXD101) and Geptanolimab
- What this could lead to
- If successful, this combination could offer a new treatment option for liver cancer patients whose tumors have stopped responding to standard immunotherapy.
- What could go wrong
- This is a small, early-phase proof-of-concept trial with only 26 participants. The approach may not work in a larger, more diverse group, and side effects from the drug combination are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Clinical Oncology, Prince of Wales Hospital
Hong Kong, Hong Kong
-
School of Biomedical Science, The Chinese University of Hong Kong
Hong Kong, Hong Kong
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A made-to-order DNA vaccine takes aim at liver cancer's return
- Simple blood test aims to catch liver cancer before It's too late
- Engineered virus takes on liver cancer when standard treatment fails
- Ultrasound vs. MRI: which spots hidden liver cancer better?
- New hope for liver cancer patients who failed immunotherapy?
- New cocktail of drugs and targeted procedure aims to control liver cancer